Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis-based diagnostics unit. The Swiss pharmaceutical and diagnostics giant ...

Roche said its $50 bil­lion promise to ex­pand its man­u­fac­tur­ing foot­print in the US has the po­ten­tial to be “re­assessed” — the same day the Swiss … ...

Biotechnology and pharmaceutical company Roche will invest up to $550 million over the next five years to expand its diagnostics manufacturing site in Indianapolis. The site is slated to become a ...

(Reuters) -Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma (ZELA.CO), opens new tab in March. This therapy is currently undergoing mid-stage clinical trials.

(Reuters) -Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the ...